Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. is well-positioned for a successful commercial launch of etripamil, bolstered by a significant increase in estimated market share for paroxysmal supraventricular tachycardia (PSVT) to 35% and a streamlined Phase 3 program for atrial fibrillation with rapid ventricular rate (AFib-RVR). The ReVeRA study's results show statistically significant improvements in symptom relief and patient-reported outcomes, enhancing the company's credibility and potential market acceptance. Furthermore, the achievement of a 100% estimated probability of success for the CARDAMYST program, coupled with positive regulatory milestones, adds strong support for shareholder value creation in the near term.

Bears say

Milestone Pharmaceuticals's stock faces a negative outlook primarily due to the uncertainties surrounding the approval and commercialization timeline of etripamil, as evidenced by the ongoing Phase 2 clinical trial for AFib-RVR. Despite the potential market opportunity, the anticipated moderation in near-term revenues raises concerns about the company's ability to achieve its projected peak annual revenues of nearly $2 billion worldwide. Furthermore, the reliance on etripamil to address an underappreciated unmet medical need may not be enough to mitigate risks associated with regulatory approvals and market competition, resulting in investor skepticism.

MIST has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 6 analysts, MIST has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.